Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig. 3 C
Maerker M et al. (2021)
|
Xla Wt + bicc1
NF20 (in situ hybridization)
|
|
|
|
Sup. Fig. 3 G I
Maerker M et al. (2021)
|
Xla Wt + bicc1 MO
NF16 (in situ hybridization)
|
|
|
|
Sup Fig. 3 G I
Maerker M et al. (2021)
|
Xla Wt + bicc1 MO
NF16 (in situ hybridization)
|
|
|
|
Fig. 3 B C
Maerker M et al. (2021)
|
Xla Wt + bicc1 MO
NF20 (in situ hybridization)
|
|
|
|
Fig. 3 D E
Maerker M et al. (2021)
|
Xla Wt + bicc1 MO
NF20 (in situ hybridization)
|
|
|
|
Fig. 4 D E
Maerker M et al. (2021)
|
Xla Wt + bicc1 MO
NF20 (in situ hybridization)
|
|
|
|
Fig. 3 A, Sup. Fig. 3 E
Maerker M et al. (2021)
|
Xla Wt + bicc1 MO
NF32 (in situ hybridization)
|
|
|
|
Fig. 3 A
Maerker M et al. (2021)
|
Xla Wt + bicc1 MO
NF32 (in situ hybridization)
|
|
|
|
Fig. 4 F G
Maerker M et al. (2021)
|
Xla Wt + bicc1 MO
NF32 (in situ hybridization)
|
|
|
|
Fig. 5 A , Sup Fig. 5 A
Maerker M et al. (2021)
|
Xla Wt + bicc1 MO + dand5 MO
NF20 (in situ hybridization)
|
|
|